Veterinary Medicines

ANTHELMIN XL 525/174, 85/175 MG COMPRIMES POUR CHIENS

Authorised
  • Febantel
  • Praziquantel
  • Pyrantel embonate
Download as PDF

Product identification

Medicine name:
ANTHELMIN XL 525/174, 85/175 MG COMPRIMES POUR CHIENS
Active substance:
  • Febantel
  • Praziquantel
  • Pyrantel embonate
Target species:
  • Dog
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Febantel
    525.00
    milligram(s)
    /
    1.00
    Tablet
  • Praziquantel
    175.00
    milligram(s)
    /
    1.00
    Tablet
  • Pyrantel embonate
    504.00
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Tablet
Withdrawal period by route of administration:
  • Oral use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP52AA51
Legal status of supply:
  • Veterinary medicinal product not subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • France
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Hybrid application (Article 13(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Hcs
Marketing authorisation date:
Manufacturing sites for batch release:
  • Krka-Farma d.o.o.
  • KRKA tovarna zdravil d.d. Novo mesto
Responsible authority:
  • French Agency For Food, Environmental And Occupational Health & Safety
Authorisation number:
  • FR/V/8762882 5/2014
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
French (PDF)
Published on: 7/04/2022
Download

Package Leaflet and Labelling

This document does not exist in this language (English). You can find it in another language below.
French (PDF)
Published on: 5/07/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."